Xbrane Biopharma Ab · OMXSTO:XBRANE
Xbrane Biopharma Ab — Q2 2026 Earnings Presentation
18 slides from Xbrane Biopharma Ab's earnings presentation, Jul 17, 2026
Slide 1: Q2 2026 Presentation - January-June 2026 Interim Report
RANE BIOPHARMA Science for high quality biosimilars RANE BIOPHARMA jo2 2026 presentation XUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January - June 2026 Interim Report 2026.07.17
Slide 2: Co-development agreement with JOINN Biologics for Xdarzane
“Co-development agreement with JOINN Biologics for Xdarzane, biosimilar candidate to Darzalex” Martin Amark, CEO July 17" , 2026 y MIBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January - June 2026 Interim Report 2026.07.17
Slide 3: Disclaimer
Disclaimer ‘You must read the following before continuing. The following applies to this document and the information provided in this presentation by Xbrane Biopharma AB (publ) (the “Company’) or any person on behalf of the Company and any other material cistributed or statements made in connection
Slide 4: Presenters
Presenters ai Martin Amark Jane Benyamin CEO CFO MIBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January - June 2026 Interim Report 2026.07.17
Slide 5: Ximluci® — Launched across countries
Ximluci® — Launched across 24 countries Ximluci® launched by STADA in 24 countries Co-Development & Commercialization Partnership with STADA > Global generics and Partnership with STADA signed in 2018. STADA are granted the commercial rights to Ximluci® globally biosimilar specialist with including
Slide 6: Ximluci® addressable market in Europe is €5 billion
Ximluci® addressable market in Europe is €5 billion > Europe retinal anti VEGF market at €5 billion in 2025 with €5 billion approx. 7 million units (excl off label Avastin) shipped 100% | ; > Volume growth of 7% p.a. and value growth of 5.5% p.a. last 3 years Europe retinal anti VEGF: EUR 5 > Partic
Slide 7: Ximluci® — Currently at 7% volume market share in Europe
Ximluci® — Currently at 7% volume market share in Europe Profit split to Xbrane and growth in vials sold by STADA > Ximluci® share of ranibizumab market across 140.0 400% launched countries in Europe was 7% by volume in Fa April 2026 119.9 120.0 tay 15.7 1149 1158 Cu5 > Shipments of final goods to S
Slide 8: Lucamzi™ — US FDA BsUFA date October 29
Lucamzi™ — US FDA BsUFA date October 29' e@ ae fae Xbrane and STADA license US commercial rights to Valorum Biologics. Valorum will be responsible for sales, * > Biosimilar commercialization Xb marketing and commercial efforts in the US after approval. STADA are responsible for completing the specia
Slide 9: Xdivane™ - on track towards US FDA BLA submission in 2027
Xdivane™ - on track towards US FDA BLA submission in 2027 2024 2025 2026 2027 2028 2029 2030 YURRANE Production of clinical material Milestone payment to Xbrane & us ae it wd A Europe > > Successful scale-up to commercial scale Conformed analytical similarity at scale Scientific advice meetings with
Slide 10: Xdarzane - Co-development agreement with JOINN Biologics
Xdarzane - Co-development agreement with JOINN Biologics Xdarzane — a USD 14 b opportunity Biosimilar candidate to Darzalex used in treatment of multiple myeloma with annual sales of USD 14 billion in 2025 Loss of Exclusivity in 2029 in US and 2031 in Europe Ongoing development of four publicly anno
Slide 11: Q2 Interim Report 2026 - Financials
Q2 Interim Report 2026 Financials January - June 2026 Interim Report 2026.07.17
Slide 12: Net Revenues (Quarter by Quarter)
Net Revenues (Quarter by Quarter) Net revenue SEK m Q2 Q3 Q4 Qt Q2 Q3 '24 '24 '24 '25 '25 ‘25 100.0 126% 80.0 60.0 40.0 20.0 - 20.0 a4 "25 Gross margin Qt ‘26 Q2 '26 % 140% 120% 100% 80% mmm Product sales (incl. Profit share) 60% Outlicensing of product 40% "== Contract manufacturing 20% Mm Other %
Slide 13: Company Expenses (G&A and R&D) by Quarter
Company Expenses (G&A and R&D inc. capitilized R&D) by Quarter Quarter by Quarter SEKm Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 0.0 10.0 218.3 95 28 01 440 -20. 31 30, be. 46, -40.0 ba -50.0 ° i) -60.0 -70.0 -80.0 90.0 G&A BR&D Q3'25 Q4'25 Q1'26 8.0 6.6 76 9.9 z XUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS Com
Slide 14: Xbrane cash flow break down during Q2 2026
Xbrane cash flow break down during Q2 2026 SEK m Cash flowchart Q2-26 > Profit sharing STADA +13 MSEK 90 13 > Production of Ximluci finished goods - 80 34 MSEK — revenue in Q2 and Q3 70 67 60 > Fixed costs -17 MSEK (salaries, social on security, IT, storage, consultants, IR etc) °° — = = @ ~34 4 > X
Slide 15: Cash Flow and Financing
Cash Flow and Financing Cash and Cash Equivalents Quarter by Quarter SEK m 140 120 100 124 94 87 80 —73 67 g 50 C 31 25 2 6 = Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 O2'26 r) é 8 ° XUBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS Cash and Cash Equivalents Amounted to ~ 49,5 MSEK end of June-26 O
Slide 16: Key Take-Aways
Key Take-Aways Ximluci® launched in 24 countries, constant market share in Europe Ongoing initiatives to reduce Ximluci production cost for long term competitiveness Ximluci BLA resubmitted in April 2026 — BSUFA date October 29% ,2026 Xdivane development proceeding according to plan targeting BLA su
Slide 17: Business Concept
BUSINESS CONCEPT Xbrane develops biosimilars of difficult-to- manufacture and often very expensive original drugs VISION To become a world-leading scientifically-based biosimilar developer of cost-effective drugs for which there is a significant medical need OBJECTIVE To contribute to everybody havi
Slide 18: MIBRANE SCIENCE FOR HIGH QUALITY
MIBRANE SCIENCE FOR HIGH QUALITY BIOSIMILARS January - June 2026 Interim Report 2026.07.17